BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 27899188)

  • 21. Bringing Prostate Cancer Germline Genetics into Clinical Practice.
    Das S; Salami SS; Spratt DE; Kaffenberger SD; Jacobs MF; Morgan TM
    J Urol; 2019 Aug; 202(2):223-230. PubMed ID: 30730411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk.
    Karlsson R; Aly M; Clements M; Zheng L; Adolfsson J; Xu J; Grönberg H; Wiklund F
    Eur Urol; 2014 Jan; 65(1):169-76. PubMed ID: 22841674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
    Casey MJ; Bewtra C
    Fam Cancer; 2004; 3(3-4):265-81. PubMed ID: 15516851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hereditary susceptibility to breast cancer: significance of age of onset in family history and contribution of BRCA1 and BRCA2.
    Frank TS; Deffenbaugh AM; Hulick M; Gumpper K
    Dis Markers; 1999 Oct; 15(1-3):89-92. PubMed ID: 10595259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate Cancer Screening in a New Era of Genetics.
    Cheng HH; Pritchard CC; Montgomery B; Lin DW; Nelson PS
    Clin Genitourin Cancer; 2017 Dec; 15(6):625-628. PubMed ID: 28697982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene analysis techniques and susceptibility gene discovery in non-BRCA1/BRCA2 familial breast cancer.
    Aloraifi F; Boland MR; Green AJ; Geraghty JG
    Surg Oncol; 2015 Jun; 24(2):100-9. PubMed ID: 25936246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A systematic review of replication studies of prostate cancer susceptibility genetic variants in high-risk men originally identified from genome-wide association studies.
    Ishak MB; Giri VN
    Cancer Epidemiol Biomarkers Prev; 2011 Aug; 20(8):1599-610. PubMed ID: 21715604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk.
    Laitinen VH; Wahlfors T; Saaristo L; Rantapero T; Pelttari LM; Kilpivaara O; Laasanen SL; Kallioniemi A; Nevanlinna H; Aaltonen L; Vessella RL; Auvinen A; Visakorpi T; Tammela TL; Schleutker J
    Cancer Epidemiol Biomarkers Prev; 2013 Mar; 22(3):452-60. PubMed ID: 23292082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate cancer susceptibility genes: lessons learned and challenges posed.
    Simard J; Dumont M; Labuda D; Sinnett D; Meloche C; El-Alfy M; Berger L; Lees E; Labrie F; Tavtigian SV
    Endocr Relat Cancer; 2003 Jun; 10(2):225-59. PubMed ID: 12790786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate cancer genetic testing: NCCN familial high-risk assessment: breast/ovarian.
    Daly MB
    Can J Urol; 2019 Oct; 26(5 Suppl 2):29-30. PubMed ID: 31629424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing.
    Rubin SC; Blackwood MA; Bandera C; Behbakht K; Benjamin I; Rebbeck TR; Boyd J
    Am J Obstet Gynecol; 1998 Apr; 178(4):670-7. PubMed ID: 9579428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations.
    Bancroft EK; Saya S; Page EC; Myhill K; Thomas S; Pope J; Chamberlain A; Hart R; Glover W; Cook J; Rosario DJ; Helfand BT; Hutten Selkirk C; Davidson R; Longmuir M; Eccles DM; Gadea N; Brewer C; Barwell J; Salinas M; Greenhalgh L; Tischkowitz M; Henderson A; Evans DG; Buys SS; ; ; Eeles RA; Aaronson NK
    BJU Int; 2019 Feb; 123(2):284-292. PubMed ID: 29802810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate cancer.
    Attard G; Parker C; Eeles RA; Schröder F; Tomlins SA; Tannock I; Drake CG; de Bono JS
    Lancet; 2016 Jan; 387(10013):70-82. PubMed ID: 26074382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A cohort analysis of men with a family history of BRCA1/2 and Lynch mutations for prostate cancer.
    Kerr L; Rewhorn MJ; Longmuir M; Fraser S; Walsh S; Andrew N; Leung HY
    BMC Cancer; 2016 Jul; 16():529. PubMed ID: 27456091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer.
    Wilkens EP; Freije D; Xu J; Nusskern DR; Suzuki H; Isaacs SD; Wiley K; Bujnovsky P; Meyers DA; Walsh PC; Isaacs WB
    Prostate; 1999 Jun; 39(4):280-4. PubMed ID: 10344217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications.
    Brandão A; Paulo P; Teixeira MR
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Germline Variants in DNA Damage Repair Genes and
    Trendowski MR; Sample C; Baird T; Sadeghpour A; Moon D; Ruterbusch JJ; Beebe-Dimmer JL; Cooney KA
    JCO Precis Oncol; 2022 Nov; 6():e2200460. PubMed ID: 36446039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
    Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
    Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.
    Giri VN; Knudsen KE; Kelly WK; Abida W; Andriole GL; Bangma CH; Bekelman JE; Benson MC; Blanco A; Burnett A; Catalona WJ; Cooney KA; Cooperberg M; Crawford DE; Den RB; Dicker AP; Eggener S; Fleshner N; Freedman ML; Hamdy FC; Hoffman-Censits J; Hurwitz MD; Hyatt C; Isaacs WB; Kane CJ; Kantoff P; Karnes RJ; Karsh LI; Klein EA; Lin DW; Loughlin KR; Lu-Yao G; Malkowicz SB; Mann MJ; Mark JR; McCue PA; Miner MM; Morgan T; Moul JW; Myers RE; Nielsen SM; Obeid E; Pavlovich CP; Peiper SC; Penson DF; Petrylak D; Pettaway CA; Pilarski R; Pinto PA; Poage W; Raj GV; Rebbeck TR; Robson ME; Rosenberg MT; Sandler H; Sartor O; Schaeffer E; Schwartz GF; Shahin MS; Shore ND; Shuch B; Soule HR; Tomlins SA; Trabulsi EJ; Uzzo R; Vander Griend DJ; Walsh PC; Weil CJ; Wender R; Gomella LG
    J Clin Oncol; 2018 Feb; 36(4):414-424. PubMed ID: 29236593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.